Product Information
OPZELURA 1.5% CREAM is a brand product labeled by Incyte Corporation, priced at $34.0119 per GM under NDC 50881000705. Its NADAC has been published 224 times since Jun 22, 2022.
FDA first approved this application on Sep 21, 2021.
Strength
15 mg/g
Manufacturer
Incyte CorporationNDC
50881000705
Classification
Brand
Dosage Form
CREAM
Route
TOPICAL
Effective Date
9/23/2026
Active Ingredients
RUXOLITINIB PHOSPHATEApproval Type
New Drug (NDA)
FDA Application
NDA215309FDA Approved
9/21/2021
On Market Since
9/21/2021
Pharmacological Classes
Price Statistics
The NADAC for OPZELURA 1.5% CREAM has been published 224 times since Jun 22, 2022, and over the history we have for it it has risen 8.9%. The table below summarizes its recorded NADAC range and movement.
| Current price | $34.0119 per GM |
|---|---|
| All-time high | $34.1433 (May 13, 2026) |
| All-time low | $31.2358 (Jun 22, 2022) |
| 52-week high | $34.1433 |
| 52-week low | $33.4719 |
| Median price | $32.8580 |
| Average price | $32.8391 |
| Largest weekly change | +3.0% (Jan 18, 2023) |
| Weeks tracked | 224 |
| Tracking since | Jun 22, 2022 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the ruxolitinib market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Incyte Corporation manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
ruxolitinib market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Janus Kinase Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of OPZELURA 1.5% CREAM?
The current National Average Drug Acquisition Cost (NADAC) for OPZELURA 1.5% CREAM, manufactured by Incyte Corporation, is $34.0119 per GM (NDC 50881000705), effective Sep 30, 2026.
How has the price of OPZELURA 1.5% CREAM changed over time?
Over the history we have for it, the NADAC for OPZELURA 1.5% CREAM has risen 8.9%. It has been tracked across 224 weekly CMS publications since Jun 22, 2022.
What are the highest and lowest recorded NADAC prices for OPZELURA 1.5% CREAM?
Since Jun 22, 2022, the NADAC for OPZELURA 1.5% CREAM has ranged from a low of $31.2358 (Jun 22, 2022) to a high of $34.1433 (May 13, 2026), with a median of $32.8580 per GM.
Are there cheaper alternatives to OPZELURA 1.5% CREAM?
No other NADAC-published product currently shares the active ingredient and strength of OPZELURA 1.5% CREAM in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures OPZELURA 1.5% CREAM?
OPZELURA 1.5% CREAM (NDC 50881000705) is labeled by Incyte Corporation, and CMS classifies it as a brand product.